Cancers 2011, 3(2), 1527-1549; doi:10.3390/cancers3021527
Review

Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy

1,†email, 2,†email and 1,3,* email
1 Department of Internal Medicine/Pathology, Karmanos Cancer Institute, Wayne State University, 4100 John R, HWCRC 732, Detroit, MI 48201, USA 2 Department of Pathology, Karmanos Cancer Institute, Wayne State University, 4100 John R, HWCRC 732, Detroit, MI 48201, USA 3 Department of Oncology, Karmanos Cancer Institute, 4100 John R, HWCRC 732, Detroit, MI 48201, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 18 February 2011; in revised form: 24 February 2011 / Accepted: 16 March 2011 / Published: 24 March 2011
(This article belongs to the Special Issue Pancreatic Cancer)
PDF Full-text Download PDF Full-Text [386 KB, Updated Version, uploaded 25 March 2011 09:56 CET]
The original version is still available [419 KB, uploaded 24 March 2011 15:22 CET]
Abstract: Pancreatic cancer (PC) has a complex etiology and displays a wide range of cellular escape pathways that allow it to resist different treatment modalities. Crucial signaling molecules that function downstream of the survival pathways, particularly at points where several of these pathways crosstalk, provide valuable targets for the development of novel anti-cancer drugs. Bcl-2 family member proteins are anti-apoptotic molecules that are known to be overexpressed in most cancers including PC. The anti-apoptotic machinery has been linked to the observed resistance developed to chemotherapy and radiation and therefore is important from the targeted drug development point of view. Over the past ten years, our group has extensively studied a series of small molecule inhibitors of Bcl-2 against PC and provide solid preclinical platform for testing such novel drugs in the clinic. This review examines the efficacy, potency, and function of several small molecule inhibitor drugs targeted to the Bcl-2 family of proteins and their preclinical progress against PC. This article further focuses on compounds that have been studied the most and also discusses the anti-cancer potential of newer class of Bcl-2 drugs.
Keywords: PC; Bcl-2 family proteins; small molecule inhibitors; apoptosis; cancer therapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Masood, A.; Azmi, A.S.; Mohammad, R.M. Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. Cancers 2011, 3, 1527-1549.

AMA Style

Masood A, Azmi AS, Mohammad RM. Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. Cancers. 2011; 3(2):1527-1549.

Chicago/Turabian Style

Masood, Ashiq; Azmi, Asfar S.; Mohammad, Ramzi M. 2011. "Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy." Cancers 3, no. 2: 1527-1549.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert